NCT Number: NCT05415098
Phase: Phase 1
Trial Summary: This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG- – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Ascentage Pharma Group Inc.
Acronym:
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives